<DOC>
	<DOCNO>NCT02553187</DOCNO>
	<brief_summary>The purpose study explore efficacy safety Kanglaite Injection treatment patient late-stage cancer cachexia .</brief_summary>
	<brief_title>A Prospective , Randomized , Controlled , Multicenter Study Kanglaite Injection Treatment Cancer Cachexia</brief_title>
	<detailed_description>The study multicenter , prospective , randomize control study . The planned sample size 160 subject . These subject randomize ( 1:1 ) treatment group ( i.e. , standard therapy plus Kanglaite Injection ) control group ( i.e. , standard therapy plus blank control ) . The study population include patient non small cell lung cancer ( adenocarcinoma ) , colorectal carcinoma pancreatic carcinoma , complicate cachexia .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<criteria>1 . Histologically confirm patient stage IIIIV nonsmall cell lung cancer ( adenocarcinoma ) , colorectal carcinoma pancreatic carcinoma , eligible surgery , interventional treatment radiation therapy ; 2 . Confirmed patient cachexia : weight loss great 5 % last six month , BMI &lt; 20kg/m2 weight loss great 2 % , accordance diagnosis sarcopenia weight loss great 2 % ; 3 . Patients treat chemotherapy complete chemotherapy 14 day randomization study ; 4 . For patient treated chemotherapy , chemotherapy regimen confine regimen specify protocol ; chemotherapy regimen , general , allow change study period ; 5 . Patients conscious able cooperate doctor complete diseaserelated examination evaluation ; 6 . ECOG performance status ( PS ) 03 treated chemotherapy ; ECOG PS 02 treat chemotherapy ; 7 . Expected survival period 4 month ; 8 . Male female age 18 75 year ; 9 . Patients willing participate study sign inform consent form . 1 . Any pathological type nonsmall cell lung cancer ( NSCLC ) except adenocarcinoma ; 2 . Patients treat chemotherapy , chemotherapy regimen among regimen specify protocol ; 3 . Patients cachexia caused reason , e.g . severe hepatic dysfunction [ Aspartate transaminase ( AST ) /Cerealthirdtransaminase ( ALT ) &gt; 5 time ULN ] , severe renal dysfunction ( Cr &gt; 1.5 time ULN ) , uncontrolled thyroid disease , New York Heart Association ( NYHA ) class IIIIV heart failure , AIDS etc . ; 4 . Any condition may hinder subject 's completion study , include limit severe uncontrollable organic disease infection , unstable angina pectoris , congestive heart failure , etc . ; 5 . Patients treat anticancer traditional Chinese medicine ( TCM ) , may treat TCM enrollment ; 6 . Patients severe hepatic dysfunction : Scr &gt; =1.5 time ULN , ALT/AST/alkaline phosphatase ( ALP ) &gt; =5 time ULN , total bilirubin ( TBIL ) &gt; =1.5 time ULN ; 7 . Patients severe abnormal lipid metabolism [ TC &gt; 300mg/dl Triglyceride ( TG ) &gt; 2.5 time ULN ] , lipidlowering therapy ; 8 . Known suspected diagnosis metastatic encephaloma ; 9 . In treatment plan receive treatment molecular target drug , eg , epidermal growth factor receptor tyrosine kinase inhibitor ( EGFRTKI ) , anaplastic lymphoma kinase ( ALK ) inhibitor , antiangiogenic agent ( include monoclonal antibody endostatin ) , cetuximab ; 10 . Patients present ECOG score &gt; 2 require treatment chemotherapy ; 11 . Patients allergies intolerability investigational product excipients ; 12 . Patients currently include clinical trial antineoplastic drug ; 13 . Patients able provide Informed Consent Form ( ICF ) ; 14 . Expected survival period le 4 month ; 15 . Female patient pregnant breastfeeding , patient childbearing age willing use method contraception ( include male ) ; 16 . Patients symptomatic , uncontrolled nervous disorder , mental illness psychiatric disorder ; 17 . Any condition , investigator 's opinion , best interest subject ( e.g. , harm subject 's health ) potentially interfere evaluation treatment accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>